{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T06:59:47Z","timestamp":1794812387341,"version":"4.9.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82273373"],"award-info":[{"award-number":["No. 82273373"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005273","name":"Natural Science Foundation of Yunnan Province","doi-asserted-by":"publisher","award":["No. 202401AS070019"],"award-info":[{"award-number":["No. 202401AS070019"]}],"id":[{"id":"10.13039\/501100005273","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005273","name":"Yunnan Natural Science Foundation","doi-asserted-by":"crossref","award":["No.202201AY070001-045"],"award-info":[{"award-number":["No.202201AY070001-045"]}],"id":[{"id":"10.13039\/501100005273","id-type":"DOI","asserted-by":"crossref"}]},{"name":"535 Talent Project of First Affiliated Hospital of Kunming Medical University","award":["No. 2023535D15"],"award-info":[{"award-number":["No. 2023535D15"]}],"id":[{"id":"https:\/\/ror.org\/02g01ht84","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Yunnan Health Training Project of High-Level Talents","award":["No. D-2024028"],"award-info":[{"award-number":["No. D-2024028"]}]},{"name":"Funding for Yunnan Province Clinical Research Center for Chronic Kidney Disease","award":["No. 202102AA10060"],"award-info":[{"award-number":["No. 202102AA10060"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate cancer continues to be a major cause of cancer-related deaths among men in the United States. Despite declining mortality rates in recent decades, variations across race, region, urban-rural status, and age remain insufficiently characterized. Therefore, updated evidence is essential to inform effective prevention and control strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prostate cancer deaths (ICD-10 code C61) among the U.S. men aged\u2009\u2265\u200945 years from 1999 to 2023 were analyzed using the CDC WONDER database. Age-adjusted mortality rate (AAMR) was calculated per 100,000 population and standardized to the 2000 U.S. standard population. Temporal trends were examined using joinpoint regression to estimate annual percent change (APC) and average APC. Subgroup analyses were conducted by region, race, urban-rural status, and age, with additional assessments at the state level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Over the 25-year study period, 749,932 prostate cancer-related deaths were reported. Mortality initially declined but began to rise after 2013, reaching a peak of 33,860 deaths in 2023, reflecting a \u2018decline followed by rebound\u2019 pattern. Importantly, the increase in absolute deaths primarily reflects the effects of population aging. The AAMR decreased significantly overall (AAPC, \u22122.20%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009.05), although the pace of decline slowed after 2013. This is likely influenced by changes in Prostate-Specific Antigen screening practices. Regionally, the South consistently exhibited the highest mortality, while the Northeast achieved the largest reduction and the West the smallest decline. By race, non-Hispanic (NH) Black men experienced the sharpest decrease yet continued to face the highest mortality, nearly twice that of NH White men. Mortality remained elevated in nonmetropolitan compared with metropolitan areas, and men aged 75 years and older continued to face the greatest risk.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>From 1999 to 2023, prostate cancer mortality among U.S. men aged 45 years and older showed a consistent decline. While the AAMR continued to decrease, the rate of decline slowed after 2013, likely due to changes in prostate-specific antigen (PSA) screening practices. In contrast, the observed rise in the absolute number of deaths mainly reflects demographic effects associated with population aging. The greatest burdens were observed among residents of the South, NH Black men, older adults, and rural populations. State-level AAMRs revealed a clear geographic gradient, with consistently higher rates in the South and lower rates in the Northeast. These findings highlight the need for future prevention and control strategies to prioritize high-risk groups through targeted interventions that promote health equity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-025-25694-6","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T08:19:46Z","timestamp":1766045986000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Temporal trends and regional disparities in prostate cancer mortality in the United States, 1999\u20132023: an analysis of the CDC WONDER database"],"prefix":"10.1186","volume":"25","author":[{"given":"Zixiong","family":"Chai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sixiang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haolin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyuan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songzhou","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengkai","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"issue":"2","key":"25694_CR1","first-page":"87","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"25694_CR2","doi-asserted-by":"crossref","unstructured":"Pujana-Vaquerizo M, Bozal-Basterra L, Carracedo A. Metabolic adaptations in prostate cancer. Br J Cancer. 2024;131(8):1250\u201362.","DOI":"10.1038\/s41416-024-02762-z"},{"key":"25694_CR3","unstructured":"American Cancer Society. 2025 Prostate Cancer Statistics. Atlanta: American Cancer Society; 2025. Available from: https:\/\/pressroom.cancer.org\/2025-Prostate-Cancer-Report."},{"key":"25694_CR4","doi-asserted-by":"crossref","unstructured":"Aziz N, Nabi W, Khan M, Gulzar AHB, Rath S, Ansab M, et al. Trends and disparities in prostate cancer mortality in the united States (1999\u20132020). Clin Genitourin Cancer. 2025;23(2):102298.","DOI":"10.1016\/j.clgc.2024.102298"},{"key":"25694_CR5","doi-asserted-by":"crossref","unstructured":"Rami A, Zhong C, Muniz M, Xie W, Khorasanchi A, Gallagher J, et al. Race and outcomes to [<\u2009sup\u2009>\u2009177\u2009Lu]Lu-PSMA-617 in advanced prostat e cancer. Cancers. 2025;17(12):1960.","DOI":"10.3390\/cancers17121960"},{"key":"25694_CR6","doi-asserted-by":"crossref","unstructured":"Lowder D, Rizwan K, McColl C, Paparella A, Ittmann M, Mitsiades N, et al. Racial disparities in prostate cancer: A complex interplay between socioeconomic inequities and genomics. Cancer Lett. 2022;531:71\u201382.","DOI":"10.1016\/j.canlet.2022.01.028"},{"issue":"4","key":"25694_CR7","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/cncr.32604","volume":"126","author":"SS Butler","year":"2020","unstructured":"Butler SS, Muralidhar V, Zhao SG, Sanford NN, Franco I, Fullerton ZH, et al. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012. Cancer. 2020;126(4):717\u201324.","journal-title":"Cancer"},{"issue":"3","key":"25694_CR8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.prnil.2018.03.001","volume":"6","author":"BM Blair","year":"2018","unstructured":"Blair BM, Robyak H, Clark JY, Kaag MG, Lehman EB, Raman JD. Impact of united States preventive services task force recommendations on prostate biopsy characteristics and disease presentation at a tertiary-care medical center. Prostate Int. 2018;6(3):110\u20134.","journal-title":"Prostate Int"},{"issue":"1","key":"25694_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1001\/jamaoncol.2021.5143","volume":"8","author":"MS Leapman","year":"2022","unstructured":"Leapman MS, Wang R, Park H, Yu JB, Sprenkle PC, Cooperberg MR, et al. Changes in prostate-specific antigen testing relative to the revised US preventive services task force recommendation on prostate cancer screening. JAMA Oncol. 2022;8(1):41\u20137.","journal-title":"JAMA Oncol"},{"key":"25694_CR10","doi-asserted-by":"crossref","unstructured":"Iyer HS, Stone BV, Roscoe C, Hsieh M-C, Stroup AM, Wiggins CL, et al. Access to prostate-Specific antigen testing and mortality among men with prostate cancer. JAMA Netw Open. 2014;7(6):e2414582.","DOI":"10.1001\/jamanetworkopen.2024.14582"},{"issue":"13","key":"25694_CR11","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1056\/NEJMsb1616281","volume":"376","author":"PF Pinsky","year":"2017","unstructured":"Pinsky PF, Prorok PC, Kramer BS. Prostate cancer Screening - A perspective on the current state of the evidence. N Engl J Med. 2017;376(13):1285\u20139.","journal-title":"N Engl J Med"},{"issue":"5","key":"25694_CR12","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1001\/jamaoncol.2016.5465","volume":"3","author":"JC Hu","year":"2017","unstructured":"Hu JC, Nguyen P, Mao J, Halpern J, Shoag J, Wright JD, et al. Increase in prostate cancer distant metastases at diagnosis in the united States. JAMA Oncol. 2017;3(5):705\u20137.","journal-title":"JAMA Oncol"},{"key":"25694_CR13","doi-asserted-by":"crossref","unstructured":"Burgess L, Aldrighetti CM, Ghosh A, Niemierko A, Chino F, Huynh MJ, et al. Association of the USPSTF grade D recommendation against prostate-Specific antigen screening with prostate Cancer\u2013Specific mortality. JAMA Netw Open. 2022;5(5):e2211869.","DOI":"10.1001\/jamanetworkopen.2022.11869"},{"key":"25694_CR14","doi-asserted-by":"crossref","unstructured":"Butler EN, Kelly SP, Coupland VH, Rosenberg PS, Cook MB. Fatal prostate cancer incidence trends in the united States and England by race, stage, and treatment. Br J Cancer. 2020;123(3):487\u201394.","DOI":"10.1038\/s41416-020-0859-x"},{"key":"25694_CR15","doi-asserted-by":"crossref","unstructured":"Drazer MW, Huo D, Eggener SE. National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen\u2013Based Screening. JCO. 2015;33(22):2416\u201323.","DOI":"10.1200\/JCO.2015.61.6532"},{"issue":"18","key":"25694_CR16","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2018.3710","volume":"319","author":"UPST Force","year":"2018","unstructured":"Force UPST. Screening for prostate cancer: US preventive services task force recommendation statement. JAMA. 2018;319(18):1901\u201313.","journal-title":"JAMA"},{"key":"25694_CR17","doi-asserted-by":"crossref","unstructured":"Iyer HS, Kensler KH, Roscoe C, Opara C, He M, Kovac E, et al. Multidimensional healthcare access barriers to Prostate-Specific antigen testing: A Nation-Wide panel study in the united States from 2006 to 2020. Cancer Med. 2024;13(21):e70358.","DOI":"10.1002\/cam4.70358"},{"key":"25694_CR18","doi-asserted-by":"crossref","unstructured":"Weiner AB, Matulewicz RS, Eggener SE, Schaeffer EM. Increasing incidence of metastatic prostate cancer in the united States (2004\u20132013). Prostate Cancer Prostatic Dis. 2016;19(4):395\u20137.","DOI":"10.1038\/pcan.2016.30"},{"issue":"5","key":"25694_CR19","doi-asserted-by":"publisher","first-page":"e2211869","DOI":"10.1001\/jamanetworkopen.2022.11869","volume":"5","author":"L Burgess","year":"2022","unstructured":"Burgess L, Aldrighetti CM, Ghosh A, Niemierko A, Chino F, Huynh MJ, et al. Association of the USPSTF grade D recommendation against prostate-specific antigen screening with prostate cancer-specific mortality. JAMA Netw Open. 2022;5(5):e2211869.","journal-title":"JAMA Netw Open"},{"key":"25694_CR20","doi-asserted-by":"crossref","unstructured":"Janopaul-Naylor JR, Corriher TJ, Switchenko J, Hanasoge S, Esdaille A, Mahal BA, et al. Disparities in time to prostate cancer treatment initiation before and after the affordable care act. Cancer Med. 2023;12(17):18258\u201368.","DOI":"10.1002\/cam4.6419"},{"key":"25694_CR21","doi-asserted-by":"crossref","unstructured":"Wang L, Lu B, He M, Wang Y, Wang Z, Du L. Prostate cancer incidence and mortality: global status and Temporal trends in 89 countries from 2000 to 2019. Front Public Health. 2022;10:811044.","DOI":"10.3389\/fpubh.2022.811044"},{"key":"25694_CR22","unstructured":"Echeverri M, Felder K, Anderson D, Apantaku E. Factors associated with knowledge, confidence, self-efficacy, and sati sfaction in African American men\u2019s decisions about prostate cancer scr eening. J Mens Health. 2025;21(1):39\u201350."},{"key":"25694_CR23","doi-asserted-by":"crossref","unstructured":"Jemal A, Culp MB, Ma J, Islami F, Fedewa SA. Prostate cancer incidence 5 years after US preventive services task force recommendations against screening. JNCI: J Natl Cancer Inst. 2021;113(1):64\u201371.","DOI":"10.1093\/jnci\/djaa068"},{"key":"25694_CR24","doi-asserted-by":"crossref","unstructured":"Brawley OW. Prostate cancer epidemiology in the united States. World J Urol. 2012;30(2):195\u2013200.","DOI":"10.1007\/s00345-012-0824-2"},{"key":"25694_CR25","doi-asserted-by":"crossref","unstructured":"Martin DN, Starks AM, Ambs S. Biological determinants of health disparities in prostate cancer. Curr Opin Oncol. 2013;25(3):235\u201341.","DOI":"10.1097\/CCO.0b013e32835eb5d1"},{"key":"25694_CR26","doi-asserted-by":"crossref","unstructured":"Murphy A, Cottrell-Daniels CC, Awasthi S, Katende E, Park JY, Denis J, et al. Understanding and addressing prostate cancer disparities in Diagnosis, Treatment, and outcomes among black men. Cancer Control. 2024;31:10732748241275389.","DOI":"10.1177\/10732748241275389"},{"key":"25694_CR27","doi-asserted-by":"crossref","unstructured":"Lopez A, Bailey JT, Galloway D, Woods-Burnham L, Montgomery SB, Kittles R, et al. Evidence-based prostate cancer screening interventions for black men: A systematic review. J Racial Ethnic Health Disparities. 2025;12(4):2734\u201342.","DOI":"10.1007\/s40615-024-02085-y"},{"key":"25694_CR28","doi-asserted-by":"crossref","unstructured":"Aladuwaka S, Alagan R, Singh R, Mishra M. Health burdens and SES in alabama: using geographic information system to examine prostate cancer health disparity. Cancers. 2022;14(19):4824.","DOI":"10.3390\/cancers14194824"},{"issue":"2","key":"25694_CR29","doi-asserted-by":"publisher","first-page":"100238","DOI":"10.1016\/j.cellin.2025.100238","volume":"4","author":"A Elbialy","year":"2025","unstructured":"Elbialy A, Sood A, Wang SJ, Wang P, Fadiel A, Parwani AV, et al. Unveiling racial disparities in prostate cancer using an integrative genomic and transcriptomic analysis. Cell Insight. 2025;4(2):100238.","journal-title":"Cell Insight"},{"key":"25694_CR30","doi-asserted-by":"crossref","unstructured":"Stevens C, Hightower A, Buxbaum SG, Falzarano SM, Rhie SK. Genomic, epigenomic, and transcriptomic signatures of prostate cancer between African American and European American patients. Front Oncol. 2023;13:1079037.","DOI":"10.3389\/fonc.2023.1079037"},{"key":"25694_CR31","doi-asserted-by":"crossref","unstructured":"Witte JS, Mefford J, Plummer SJ, Liu J, Cheng I, Klein EA, et al. HOXB13 mutation and prostate cancer: studies of siblings and aggressive disease. Cancer Epidemiol Biomarkers Prev. 2013;22(4):675\u201380.","DOI":"10.1158\/1055-9965.EPI-12-1154"},{"issue":"38","key":"25694_CR32","doi-asserted-by":"publisher","first-page":"14068","DOI":"10.1073\/pnas.0605832103","volume":"103","author":"ML Freedman","year":"2006","unstructured":"Freedman ML, Haiman CA, Patterson N, McDonald GJ, Tandon A, Waliszewska A, et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci USA. 2006;103(38):14068\u201373.","journal-title":"Proc Natl Acad Sci USA"},{"key":"25694_CR33","doi-asserted-by":"crossref","unstructured":"Haiman CA, Patterson N, Freedman ML, Myers SR, Pike MC, Waliszewska A, et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet. 2007;39(5):638\u201344.","DOI":"10.1038\/ng2015"},{"key":"25694_CR34","doi-asserted-by":"crossref","unstructured":"Cobbs Ct, Chesnut GT, Shafi AA. Understanding Racial disparities in prostate cancer: A multifaceted approach. Cancer Med. 2025;14(11):e70979.","DOI":"10.1002\/cam4.70979"},{"key":"25694_CR35","doi-asserted-by":"crossref","unstructured":"Lee JR, Morehead D, Young B, Tolbert V, Masembe J, Britt G, et al. Patient and physician perceptions of Prostate-Specific antigen testing among black individuals. JAMA Netw Open. 2025;8(9):e2530946.","DOI":"10.1001\/jamanetworkopen.2025.30946"},{"key":"25694_CR36","doi-asserted-by":"crossref","unstructured":"Zavala VA, Bracci PM, Carethers JM, Carvajal-Carmona L, Coggins NB, Cruz-Correa MR, et al. Cancer health disparities in racial\/ethnic minorities in the united States. Br J Cancer. 2021;124(2):315\u201332.","DOI":"10.1038\/s41416-020-01038-6"},{"issue":"4","key":"25694_CR37","first-page":"417","volume":"20","author":"LX Clegg","year":"2009","unstructured":"Clegg LX, Reichman ME, Miller BA, Hankey BF, Singh GK, Lin YD, et al. Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the Surveillance, epidemiology, and end results: National longitudinal mortality study. Cancer Causes Control. 2009;20(4):417\u201335.","journal-title":"Cancer Causes Control"},{"issue":"3","key":"25694_CR38","doi-asserted-by":"publisher","first-page":"e242852","DOI":"10.1001\/jamanetworkopen.2024.2852","volume":"7","author":"A Wadhwa","year":"2024","unstructured":"Wadhwa A, Roscoe C, Duran EA, Kwan L, Haroldsen CL, Shelton JB, et al. Neighborhood deprivation, race and ethnicity, and prostate cancer outcomes across California health care systems. JAMA Netw Open. 2024;7(3):e242852-e.","journal-title":"JAMA Netw Open"},{"key":"25694_CR39","doi-asserted-by":"crossref","unstructured":"Du XL, Gao D, Li Z. Incidence trends in prostate cancer among men in the United States fro m 2000 to 2020 by race and ethnicity, age and tumor stage. Frontiers in oncology. 2023;13:1292577.","DOI":"10.3389\/fonc.2023.1292577"},{"key":"25694_CR40","doi-asserted-by":"crossref","unstructured":"Jani C, Mouchati C, Abdallah N, Mariano M, Jani R, Salciccioli JD, et al. Trends in prostate cancer mortality in the united States of America, by state and race, from 1999 to 2019: estimates from the centers for disease control WONDER database. Prostate Cancer Prostatic Dis. 2023;26(3):552\u201362.","DOI":"10.1038\/s41391-022-00628-0"},{"key":"25694_CR41","doi-asserted-by":"crossref","unstructured":"Pandit AA, Patil NN, Mostafa M, Kamel M, Halpern MT, Li C. Rural-Urban disparities in patient care experiences among prostate cancer survivors: A SEER-CAHPS study. Cancers (Basel). 2023;15(7):1939.","DOI":"10.3390\/cancers15071939"},{"key":"25694_CR42","doi-asserted-by":"crossref","unstructured":"Maganty A, Sabik LM, Sun Z, Eom KY, Li J, Davies BJ, et al. Under treatment of prostate cancer in rural locations. J Urol. 2020;203(1):108\u201314.","DOI":"10.1097\/JU.0000000000000500"},{"issue":"Suppl 4","key":"25694_CR43","first-page":"s41","volume":"32","author":"HW Chin","year":"2015","unstructured":"Chin HW, Kim J, Rasp G, Hristov B. Prostate cancer in seniors: part 1: Epidemiology, Pathology, and screening. Fed Pract. 2015;32(Suppl 4):s41\u20134.","journal-title":"Fed Pract"},{"issue":"1","key":"25694_CR44","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1186\/s12885-025-13961-z","volume":"25","author":"M Bonneau","year":"2025","unstructured":"Bonneau M, Steinmeyer Z, Morisseau M, Lozano S, Barbe P, Chauvet C, et al. Impact of comprehensive geriatric assessment on treatment decisions in older prostate cancer patients. BMC Cancer. 2025;25(1):642.","journal-title":"BMC Cancer"},{"issue":"Suppl 7","key":"25694_CR45","first-page":"s36","volume":"32","author":"HW Chin","year":"2015","unstructured":"Chin HW, Kim J, Rasp G, Hristov B. Prostate cancer in male seniors part 2: treatment. Fed Pract. 2015;32(Suppl 7):s36\u201340.","journal-title":"Fed Pract"},{"key":"25694_CR46","unstructured":"Graham LS, Lin JK, Lage DE, Kessler ER, Parikh RB, Morgans AK. Management of Prostate Cancer in Older Adults. American Society of Clinical Oncology Educational Book. (43)."},{"key":"25694_CR47","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 73(1):17\u201348.","DOI":"10.3322\/caac.21763"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-25694-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-025-25694-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-25694-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T08:20:07Z","timestamp":1766046007000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12889-025-25694-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["25694"],"URL":"https:\/\/doi.org\/10.1186\/s12889-025-25694-6","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4263"}}